Camp4 Therapeutics Corp. (CAMP) – Form 4 insider filing
On 06/25/2025, director Richard A. Young received a grant of 9,000 stock options with an exercise price of $1.56 per share. The award was recorded with transaction code “A,” indicating a new acquisition rather than an exercise or sale. All options vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the company’s next annual meeting of stockholders, subject to Mr. Young’s continued board service. The options expire on 06/24/2035.
Following the grant, Mr. Young beneficially owns 9,000 derivative securities linked to CAMP common stock, held directly. No open-market purchases or sales of common shares were reported, and no price was paid for the option grant itself.
Key takeaways for investors
- Routine director compensation: single option grant, modest in size.
- No indication of insider buying or selling of existing shares.
- Grant terms align with standard governance practices (10-year life, one-year vesting).
Camp4 Therapeutics Corp. (CAMP) filed a Form 4 detailing a routine director equity grant. On 06/25/2025, director Michael J. Higgins received a stock option covering 9,000 common shares at an exercise price of $1.56 per share. The option vests in full on the earlier of (i) the first anniversary of the grant date or (ii) the company’s next annual shareholders’ meeting, provided Mr. Higgins remains on the board. The option expires on 06/24/2035. Following the transaction, Mr. Higgins beneficially owns 9,000 derivative securities (options) and disclosed no additional direct or indirect common-stock holdings.
The filing was signed on 06/27/2025 by Josh Mandel-Brehm as Attorney-in-Fact.
Camp4 Therapeutics Corp. (CAMP) – Form 4 insider transaction
Director and 10% owner Andrew J. Schwab reported the grant of 9,000 non-qualified stock options on 25 June 2025. The options carry an exercise price of $1.56 per share and expire on 24 June 2035, providing a 10-year term.
- Vesting: The entire award vests on the earlier of (i) the first anniversary of the grant date or (ii) the next annual meeting of stockholders, subject to Mr. Schwab’s continued board service.
- Ownership status: All 9,000 options are held directly by the reporting person; the filing shows no prior derivative holdings, so the post-grant balance is 9,000 options.
- Transaction code “A” denotes an award rather than an open-market purchase or sale; no cash consideration was paid for the grant (price indicated as $0).
The filing does not disclose any accompanying sales or acquisitions of common shares, nor does it provide earnings or operational data. As such, the Form 4 primarily signals continued equity-based incentive alignment between the director/large shareholder and outside investors.
Camp4 Therapeutics Corp. (CAMP) filed a Form 4 disclosing a routine equity compensation grant to director and 10% owner Amir Nashat. On 06/25/2025 Nashat received 9,000 non-qualified stock options with an exercise price of $1.56 per share. All options vest on the earlier of (i) the first anniversary of the grant or (ii) the company’s next annual shareholder meeting, provided Nashat continues to serve on the board through that date. The options carry a 10-year term expiring 06/24/2035 and were reported as direct beneficial ownership. No shares of common stock were bought or sold; the filing reflects only the grant of derivative securities. The size of the award is modest and does not materially change the company’s share count or insider ownership profile.